ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences:

  • Financial Times Pharma and Biotech Summit in London

    Format: Industry Panel

    Date and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ET

    Conference link:
  • Credit Suisse Annual Healthcare Conference in Southern California

    Format: Fireside Chat

    Date and Time: Wednesday, November 9th, 4:35 p.m. – 6:35 p.m. ET

    Conference link:
  • HLTH in Las Vegas

    Format: Industry Panel

    Date and Time: Monday, November 14th, 7:20 p.m. - 8:00 p.m. ET

    Conference link:
  • Jefferies Healthcare Conference in London

    Format: Fireside Chat

    Date and Time: Wednesday, November 16th, 8:00 a.m. – 8:30 a.m. GMT

    Conference link:
  • Collaborating for Novel Solutions (CNS) Summit in Boca Raton, Florida

    Format: Keynote Industry Panel

    Date and Time: Saturday, November 19th, 12 p.m. – 12:30 p.m. ET

    Conference link:

Certain events will have archived webcasts available in the section of atai’s website at , where they will be available for up to 90 days.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

Contact Information

Investor Contact:

Stephen Bardin

Chief Financial Officer

Email:

Media Contact:

Allan Malievsky

Senior Director of External Affairs

Email:  



EN
01/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE

atai Life Sciences Announces Positive Topline Data from Part 2 of Beck...

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing - Data from the eight-week core, randomized stage of Beckley Psytech’s Phase 2b study of BPL-003 for treatment-resista...

 PRESS RELEASE

atai Life Sciences Reports First Quarter 2025 Financial Results and Re...

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S.Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment of ...

 PRESS RELEASE

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of E...

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo-controlled Phase 2 study will assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder - Topline data anticipated in the first quarter of 2026 NEW YORK and BERLIN, May 13, 2025 (GLOBE...

 PRESS RELEASE

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial...

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights  - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipate...

 PRESS RELEASE

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase...

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch